Orchestra Biomed Holdings, Inc. (OBIO)
NASDAQ:OBIO
Top Page
Orchestra BioMed Holdings
(NASDAQ:OBIO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.50
▲(4.65% Upside)
Action:ReiteratedDate:03/12/26
The score is held back primarily by heavy ongoing losses and significant cash burn despite strong gross margins and a recent revenue inflection. Technicals are supportive with price above major moving averages and positive momentum indicators, while valuation remains constrained by negative earnings. Corporate events add some support via expected cash proceeds and execution-focused incentives.
Positive Factors
High-margin revenue step-up
A substantial TTM revenue increase alongside ~93% gross margin indicates the company is generating high-value, scalable revenue likely tied to device/partnership economics. High gross margins support durable unit economics and provide a foundation for future operating leverage if fixed costs are absorbed as revenue scales.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow near -$49M TTM means the business is not self-funding. Continued cash burn requires recurring external financing, raising dilution risk and creating dependency on capital markets or partners to sustain pivotal trials and commercialization efforts over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High-margin revenue step-up
A substantial TTM revenue increase alongside ~93% gross margin indicates the company is generating high-value, scalable revenue likely tied to device/partnership economics. High gross margins support durable unit economics and provide a foundation for future operating leverage if fixed costs are absorbed as revenue scales.
Read all positive factors
Orchestra BioMed Holdings (OBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$251.64M
Dividend YieldN/A
Average Volume (3M)206.65K
Price to Earnings (P/E)―
Beta (1Y)1.81
Revenue Growth6.46%
EPS Growth-14.32%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.12
Shares Outstanding58,520,900
10 Day Avg. Volume105,584
30 Day Avg. Volume206,648
Financial Highlights & Ratios
PEG Ratio90.81
Price to Book (P/B)2.51K
Price to Sales (P/S)4758.67
P/FCF Ratio-3.22K
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue7.82
Enterprise Value/Gross Profit7.86
Enterprise Value/Ebitda-5.10
Forecast
1Y Price Target
$13.40Price Target Upside211.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$1.68M
Orchestra BioMed Holdings Business Overview & Revenue Model
Company Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Bal...
How the Company Makes Money
null...
Orchestra BioMed Holdings Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 33.48M | 2.64M | 2.76M | 3.53M | -782.00K |
| Gross Profit | 33.29M | 2.43M | 2.57M | 3.21M | -981.00K |
| EBITDA | -51.48M | -63.99M | -51.22M | -32.44M | -21.62M |
| Net Income | -52.95M | -61.02M | -49.12M | -33.61M | -23.01M |
Balance Sheet | |||||
| Total Assets | 114.86M | 76.17M | 95.21M | 95.57M | 13.53M |
| Cash, Cash Equivalents and Short-Term Investments | 106.51M | 66.81M | 87.59M | 83.78M | 10.90M |
| Total Debt | 1.69M | 16.53M | 1.69M | 11.87M | 5.67M |
| Total Liabilities | 51.48M | 43.22M | 27.17M | 43.04M | 84.76M |
| Stockholders Equity | 63.38M | 32.96M | 68.04M | 52.53M | -71.23M |
Cash Flow | |||||
| Free Cash Flow | -49.45M | -50.85M | -46.20M | -29.88M | -19.70M |
| Operating Cash Flow | -48.96M | -50.56M | -46.13M | -29.29M | -19.43M |
| Investing Cash Flow | -26.94M | 13.09M | 10.69M | -64.12M | 13.02M |
| Financing Cash Flow | 88.33M | 29.17M | 46.22M | 103.26M | -3.99M |
Orchestra BioMed Holdings Technical Analysis
Positive
4.30
Price Trends
4.27
Positive
4.35
Positive
3.69
Positive
Market Momentum
-0.02
Positive
55.76
Neutral
55.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Positive. The current price of 4.3 is below the 20-day moving average (MA) of 4.40, above the 50-day MA of 4.27, and above the 200-day MA of 3.69, indicating a bullish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 55.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OBIO.
Orchestra BioMed Holdings Risk Analysis
Orchestra BioMed Holdings disclosed 80 risk factors in its most recent earnings report. Orchestra BioMed Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We may not be able to borrow additional funds under the 2024 LSA, and the terms of the 2024 LSA place restrictions on our operating and financial flexibility. Q3, 2024
Orchestra BioMed Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $251.64M | -3,008.78 | -169.64% | ― | 6.46% | -14.32% | |
52 Neutral | $412.24M | -4.53 | -33.41% | ― | ― | 64.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $87.07M | -8.98 | -109.73% | ― | ― | 50.39% | |
46 Neutral | $108.70M | -4.09 | -82.00% | ― | -27.29% | 16.40% | |
46 Neutral | $107.44M | -0.90 | -87.28% | ― | -82.53% | -52.00% |
* Healthcare Sector Average
OBIO
Orchestra BioMed Holdings
4.51
1.69
59.93%
CRDF
Cardiff Oncology
1.63
-1.31
-44.56%
GLSI
Greenwich LifeSciences
26.02
17.07
190.73%
CLYM
Climb Bio
8.85
7.49
550.74%
CGTX
Cognition Therapeutics
0.98
0.60
156.58%
PYXS
Pyxis Oncology
1.70
0.78
84.78%
Orchestra BioMed Holdings Corporate Events
Business Operations and StrategyExecutive/Board Changes
Orchestra BioMed Adopts 2026 Performance-Driven Executive Compensation Plan
Positive
Feb 13, 2026
On February 12, 2026, Orchestra BioMed Holdings, Inc.’s board of directors approved a 2026 cash bonus plan for its executive officers that ties payouts to mid-year and full-year performance against clinical, financial, and operational goals,...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Orchestra BioMed gains cash from Vivasure sale proceeds
Positive
Jan 12, 2026
On January 12, 2026, Orchestra BioMed announced it expects to receive up to $21 million in cash proceeds following the January 9, 2026 closing of Haemonetics Corporation’s acquisition of its long-held strategic investment Vivasure Medical, a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.